



ASX ANNOUNCEMENT

29 April 2024

Opyl Limited (ASX: OPL) Expands TrialKey Coverage, Revolutionising AI Clinical Trial Prediction and Design Optimisation

Key highlights:

- **Expanded Dataset for Deeper Insights:** TrialKey has significantly broadened its AI-driven dataset, now providing predictions and insights based on a vast repository of over 350,000+ trials sourced from clinicaltrials.gov. This marks a substantial increase from its previous coverage of 65,000 trials.
- **Insight Extraction with AI:** Utilising advanced Large Language Model (LLM) techniques, TrialKey effectively extracts crucial details from free-text entries in clinical trials, facilitating insightful analysis.
- **Enhanced AI-Driven Trial Coverage:** TrialKey now encompasses a wider array of trials, including those focused on medical devices, alternative therapies, and non-randomised control trials. This expanded coverage creates fresh avenues for stakeholders in these sectors to utilise TrialKey's design engine effectively, thereby amplifying its impact and market applications.

Melbourne, Australia – Opyl Limited (ASX:OPL) (the “Company”) is pleased to announce Opyl's recent expansion of its TrialKey.ai AI-driven platform marking a significant milestone in the realm of clinical trial prediction and design optimisation. By widening TrialKey's coverage from 65,000 to 350,000 trials, Opyl has significantly bolstered its capacity to offer comprehensive insights into the complexities of clinical research and design.

At the heart of this expansion lies the integration of advanced AI based Large Language Model (LLM.) Through LLMs, TrialKey meticulously analyses the free-text entries recorded by clinicians in clinical trials, extracting crucial information such as dosages, administration methods, mechanisms of action, inclusion/exclusion criteria, among other key details. This proprietary approach not only ensures remarkable accuracy but also scalability, empowering TrialKey to efficiently process vast amounts of textual data from clinical trials. By transforming unstructured data into structured data, TrialKey can incorporate these variables into its modelling approach.

The expanded coverage of TrialKey now encompasses a diverse array of trials, ranging from those involving medical devices to alternative therapies and non-randomised drug control trials. This broader spectrum of coverage furnishes trial designers and stakeholders with a richer dataset for in-depth analysis and optimisation, thereby advancing the field of clinical research and design.

"Expanding our coverage now means that our clinical design module can be utilised on any trial worldwide, regardless of phase," emphasises Saurabh Jain, highlighting TrialKey's trial completeness. "Moreover, TrialKey's algorithm has uncovered that over half of the trials conducted globally could have been significantly enhanced by addressing simple trial design optimisation opportunities. By pinpointing these readily addressable changes that can



boost the likelihood of success. TrialKey empowers stakeholders to rectify design flaws proactively. Considering that the typical phase of a 2 study, these pre-emptive adjustments not only save time and money but also heighten the probability of advancing to FDA approval."

In recent studies employing holdout datasets, TrialKey has showcased robust predictive capabilities. With a precision exceeding 90%¹, the algorithm accurately identifies a significant portion of actual positives, underscoring its efficacy in guiding decision-making processes for pharmaceutical companies, Clinical Research Organizations (CROs), and clinical trial investors. These findings underscore TrialKey's pivotal role in expediting therapeutic development and refining trial design processes.

As Opyl continues to innovate and lead in the healthcare and pharmaceutical sectors, its TrialKey platform remains at the forefront. Leveraging advanced analytics and machine learning techniques, TrialKey drives actionable insights and facilitates informed decision-making, further solidifying its position as an indispensable tool in the quest for improved healthcare outcomes. For more information about Opyl Limited and its TrialKey platform, please visit <http://opyl.ai>.

The Board has authorised this announcement for release to the ASX.

-ENDS-

For investor enquiries:

Saurabh Jain
Interim CEO
Phone: +61 400 748 587
Email: saurabh@opyl.ai

For general enquiries:

Email: info@opyl.ai
Website: www.opyl.ai

About Opyl Limited (ASX: OPL)

Opyl Limited is an AI company dedicated to leveraging data and technology to transform the landscape of clinical trials and medical research. With a commitment to innovation and strategic growth, Opyl is positioned to lead the way in shaping the future of healthcare solutions.

¹ TrialKey analysis with data sourced from <https://clinicaltrials.gov/>